title: A phase II trial of cisplatin and 5-fluorouracil with allopurinol for recurrent or metastatic carcinoma of the uterine cervix: a Southwest Oncology Group trial.
abstract: On the strength of recent evidence of the activity of the combination of cisplatin and 5-fluorouracil against squamous malignancies of the esophagus and head and neck, this regimen was evaluated in a phase II trial against metastatic or recurrent squamous carcinoma of the uterine cervix. Cisplatin was administered at a dosage of 100 mg/m2 iv bolus and 5-fluorouracil was continuously infused iv at a dosage of 1000 mg/m2/day for 4 days. In an effort to determine whether the toxicities of 5-fluorouracil could be ameliorated by coadministration of allopurinol, patients were randomized to receive allopurinol, 900 mg orally, an odd or even courses of therapy beginning 5 days before 5-fluorouracil administration and continuing until conclusion of the infusion. Fifty-two eligible patients received 177 evaluable courses of treatment. The overall response rate was 28% (8 complete responses and 6 partial responses). Toxicity was confined to nausea and vomiting (81% of courses), anemia (47%), leukopenia (37%), oral mucositis (15%), diarrhea (6%), and thrombocytopenia (4%). Allopurinol produced no improvement in treatment-related toxicities. Allopurinol did not permit substantial increases in 5-fluorouracil dosage.
authors.affiliation: University of Texas Health Science Center, San Antonio.
authors.forename: G R
authors.initials: GR
authors.lastname: Weiss
authors.forename: S
authors.initials: S
authors.lastname: Green
authors.forename: E V
authors.initials: EV
authors.lastname: Hannigan
authors.forename: J G
authors.initials: JG
authors.lastname: Boutselis
authors.forename: E A
authors.initials: EA
authors.lastname: Surwit
authors.forename: D L
authors.initials: DL
authors.lastname: Wallace
authors.forename: D S
authors.initials: DS
authors.lastname: Alberts
mesh_terms: D000328:Adult; D000368:Aged; D000493:Allopurinol / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001772:Blood Cell Count / Q000187:drug effects; D002277:Carcinoma / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary; D002945:Cisplatin / Q000008:administration & dosage; D004341:Drug Evaluation; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D013534:Survival; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary
chemical_list: D000493:Allopurinol; D002945:Cisplatin; D005472:Fluorouracil